pharma · Muscle-invasive bladder cancer (MIBC) · Acute ischaemic stroke due to basilar artery occlusion.
Tour Hekla
Tour Hekla clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Puteaux, Ile de France 92800, FR
- Employees
- 6
- Programs
- 27
- Drugs
- 71
- Patents
- 0
Tour Hekla projects
5 ClinicalTrials.gov programs sponsored by Tour Hekla.
Tour Hekla has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CARVECIR
Tour Hekla
Asymptomatic Child-Pugh A5 to B8 cirrhosis
1 trial -
DR200090
Tour Hekla
Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening
1 trial -
DR230314
Tour Hekla
Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.
1 trial -
DR240305
Tour Hekla
Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).
1 trial -
PHARBEVACOL
Tour Hekla
1st line treatment for unresectable metastatic colorectal cancer
1 trial
Frequently asked questions
How many clinical projects does Tour Hekla have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.